C-Met inhibitors

Infectious Agents and Cancer

Volumn 8, Issue 1, 2013, Pages

  Mughal, Anum ^a   Aslam, Hafiz Muhammad ^a   Sheikh, Asfandyar ^a,b   Khan, Agha Muhammad Hammad ^c   Saleem, Shafaq ^a  

^a DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b Pakistan Research Evolution Scientific Society   (Pakistan)

^c DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

Author keywords

c Met; Cancer; Tyrosine kinase

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; BETA CATENIN; BMS 777607; CABOZANTINIB; FORETINIB; JNJ 38877605; MK 2461; PF 04217903; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CATALYSIS; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SOLID TUMOR;

EID: 84875860383     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-8-13     Document Type: Article

References (27)

1. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R, Cytokine Growth Factor Rev 2002 13 1 41 10.1016/S1359-6101(01)00029-6 11750879
2. Localization of the 5'end of the MCF2 oncogene to human chromosome 15q15→ q23. Galland F, Stefanova M, Lafage M, Birnbaum D, Cytogenet Genome Res 1992 60 2 114 116 10.1159/000133316
3. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Bottaro DP, Rubin JS, Faletto DL, Chan A, Kmiecik TE, Vande WG, Aaronson SA, Science 1991 251 4995 802 New York, NY 10.1126/science.1846706 1846706
4. Small molecule c-Met kinase inhibitors: a review of recent patents. Porter J, Expert Opin Ther Pat 2010 20 2 159 177 10.1517/13543770903514137 20100000
5. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Cancer Res 2003 63 21 7345 7355 14612533
6. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Comoglio PM, Giordano S, Trusolino L, Nat Rev Drug Discov 2008 7 6 504 516 10.1038/nrd2530 18511928
7. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE, Cancer Res 2010 70 2 639 645 10.1158/0008-5472.CAN-09-1121 20068147
8. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, Valente G, Giordano S, Cortesina G, Comoglio PM, Oncogene 2000 19 12 1547 1555 10.1038/sj.onc.1203455 10734314
9. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee KS, Cancer Res 1999 59 2 307 310 9927037
10. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Nat Genet 1997 16 1 68 73 10.1038/ng0597-68 9140397
11. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Christensen JG, Burrows J, Salgia R, Cancer Lett 2005 225 1 1 26 10.1016/j.canlet.2004.09.044 15922853
12. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Liu X, Newton RC, Scherle PA, Trends Mol Med 2010 16 1 37 45 10.1016/j.molmed.2009.11.005 20031486
13. The MET axis as a therapeutic target. Sattler M, Salgia R, Update Cancer Ther 2009 3 3 109 118 10.1016/j.uct.2009.01.001 20368753
14. ERK and MMPs sequentially regulate distinct stages of epithelial tubule development. O'Brien LE, Tang K, Kats ES, Schutz-Geschwender A, Lipschutz JH, Mostov KE, Dev Cell 2004 7 1 21 32 10.1016/j.devcel.2004.06.001 15239951
15. The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. Graziani A, Gramaglia D, Cantley L, Comoglio P, J Biol Chem 1991 266 33 22087 22090 1718989
16. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Monga SP, Mars WM, Pediaditakis P, Bell A, Mule K, Bowen WC, Wang X, Zarnegar R, Michalopoulos GK, Cancer Res 2002 62 7 2064 2071 11929826
17. Regulation of c-Met-dependent gene expression by PTEN. Abounader R, Reznik T, Colantuoni C, Martinez-Murillo F, Rosen EM, Laterra J, Oncogene 2004 23 57 9173 9182 15516982
18. HGF/c-Met and cancer http://www.healthvalue.net/c-metandcancer.html
19. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Wang X, Le P, Liang C, Chan J, Kiewlich D, Miller T, Harris D, Sun L, Rice A, Vasile S, Mol Cancer Ther 2003 2 11 1085 1092 14617781
20. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Dussault I, Bellon SF, Anti-Cancer Agents Med Chem 2009 9 2 221 229 10.2174/187152009787313792
21. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, Ashwell MA, Chan TC, J Biol Chem 2011 286 23 20666 20676 10.1074/jbc.M110.213801 21454604
22. Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Underiner TL, Herbertz T, Miknyoczki SJ, Anti-Cancer Agents Med Chem 2010 10 1 7 10.2174/1871520611009010007
23. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, J Clin Oncol 2013 31 2 181 6 10.1200/JCO.2012.43.3383 23213094
24. FDA approves Cometriq to treat rare type of thyroid cancer http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm330143.htm
25. Cometriq prescribing information http://www.exelixis.com/sites/default/ files/pdf/COMETRIQ%20Prescribing%20Information.pdf
26. FORETINIB. Huang P, Drugs Future 2011 35 11 893 901
27. Clouds with silver lining: defining conditions that serve as blessings in disguise. Anwer SMS, Ansari MH, El Mednifico J 2012 1 1 19